- id: A1
  description: Any drug prescribed without a clinical indication.
  substances: []
  enabled: true
  phase: STOPP
- id: A2
  description: Any drug prescribed beyond the recommended duration, where treatment
    duration is well defined.
  substances: []
  enabled: true
  phase: STOPP
- id: A3
  description: Any duplicate drug class prescription for daily regular use (as distinct
    from PRN use) e.g., two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors,
    anticoagulants, antipsychotics, opioid analgesics (optimisation of monotherapy
    within a single drug class should be observed prior to considering a new agent).
  substances:
  - ACE
  - NSAID
  - PRN
  - SSRI
  enabled: true
  phase: STOPP
- id: B1
  description: Digoxin for heart failure with normal systolic ventricular function
    (no clear evidence of benefit)
  substances: []
  enabled: true
  phase: STOPP
- id: B2
  description: Verapamil or diltiazem with NYHA Class III or IV heart failure (may
    worsen heart failure with reduced ejection fraction i.e., HFREF).
  substances:
  - HFREF
  - III
  - NYHA
  enabled: true
  phase: STOPP
- id: B3
  description: Beta-blocker in combination with verapamil or diltiazem (risk of heart
    block).
  substances: []
  enabled: true
  phase: STOPP
- id: B4
  description: Ventricular rate-limiting drugs i.e., beta blocker, verapamil, diltiazem,
    digoxin with bradycardia (< 50/min), type II heart block or complete heart block
    (risk of complete heart block, asystole).
  substances: []
  enabled: true
  phase: STOPP
- id: B5
  description: Beta-blocker as monotherapy for uncomplicated hypertension i.e., not
    associated with angina pectoris, aortic aneurysm or other condition where beta-blocker
    therapy is indicated (no firm evidence of efficacy).
  substances: []
  enabled: true
  phase: STOPP
- id: B6
  description: Amiodarone as first-line antiarrhythmic therapy in supraventricular
    tachyarrhythmias (higher risk of major side-effects than beta-blockers, digoxin,
    verapamil or diltiazem).
  substances: []
  enabled: true
  phase: STOPP
- id: B7
  description: Loop diuretic as first-line treatment for hypertension unless there
    is concurrent heart failure requiring diuretic therapy (safer, more effective
    alternatives available).
  substances: []
  enabled: true
  phase: STOPP
- id: B8
  description: Loop diuretic for dependent ankle oedema without clinical, biochemical
    or radiological evidence of heart failure, liver failure, nephrotic syndrome or
    renal failure (leg elevation and /or compression hosiery usually more appropriate).
  substances: []
  enabled: true
  phase: STOPP
- id: B9
  description: Thiazide diuretic with current significant hypokalaemia (i.e., serum
    K+ < 3.0 mmol/l), hyponatraemia (i.e., serum Na+ < 130 mmol/l) hypercalcaemia
    (i.e., corrected serum calcium > 2.65 mmol/l) or with a history of gout (hypokalaemia,
    hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)
  substances: []
  enabled: true
  phase: STOPP
- id: B10
  description: Loop diuretic for treatment of hypertension with concurrent urinary
    incontinence (may exacerbate incontinence).
  substances: []
  enabled: true
  phase: STOPP
- id: B11
  description: Centrally-acting antihypertensives e.g., methyldopa, clonidine, moxonidine,
    rilmenidine, guanfacine (centrally-active antihypertensives are generally less
    well tolerated by older people than younger people)
  substances: []
  enabled: true
  phase: STOPP
- id: B12
  description: Angiotensin-Converting Enzyme inhibitors (ACEIs) or Angiotensin Receptor
    Blockers (ARBs) in patients with hyperkalaemia i.e., serum K > 5.5 mmol/l.
  substances:
  - ACEI
  - ARB
  enabled: true
  phase: STOPP
- id: B13
  description: Aldosterone antagonists (e.g., spironolactone, eplerenone) with concurrent
    potassium- conserving drugs (e.g., ACEI’s, ARB’s, amiloride, triamterene) without
    monitoring of serum potassium (risk of dangerous hyperkalaemia i.e., > 6.0 mmol/l
    – serum K should be monitored regularly, i.e., at least every 6 months).
  substances:
  - ACEI
  - ARB
  enabled: true
  phase: STOPP
- id: B14
  description: Phosphodiesterase type-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil)
    in severe heart failure characterised by hypotension i.e., systolic BP < 90 mmHg,
    or concurrent nitrate therapy for angina (risk of cardiovascular collapse).
  substances: []
  enabled: true
  phase: STOPP
- id: B15
  description: Drugs that predictably prolong the QTc interval (QTc = QT/RR) in patients
    with known with demonstrable QTc prolongation (to >450 msec in males and >470
    msec in females), including quinolones, macrolides, ondansetron, citalopram (doses
    > 20 mg/day), escitalopram (doses > 10 mg/day), tricyclic antidepressants, lithium,
    haloperidol, digoxin, class 1A antiarrhythmics, class III antiarrhythmics, tizanidine,
    phenothiazines, astemizole, mirabegron (risk of life- threatening ventricular
    arrhythmias).
  substances:
  - III
  enabled: true
  phase: STOPP
- id: B16
  description: Statins for primary cardiovascular prevention in persons aged ≥ 85
    and established frailty with expected life expectancy likely less than 3 years
    (lack of evidence of efficacy).
  substances: []
  enabled: true
  phase: STOPP
  age_min: 85
- id: B17
  description: Long-term systemic i.e., non-topical NSAIDs with known history of coronary,
    cerebral or peripheral vascular disease (increased risk of thrombosis).
  substances:
  - NSAID
  enabled: true
  phase: STOPP
- id: B18
  description: Long-term antipsychotics with known history of coronary, cerebral or
    peripheral vascular disease (increased risk of thrombosis).
  substances: []
  enabled: true
  phase: STOPP
- id: B19
  description: NSAIDs or systemic corticosteroids with heart failure requiring loop
    diuretic therapy (risk of exacerbation of heart failure).
  substances:
  - NSAID
  enabled: true
  phase: STOPP
- id: B20
  description: Antihypertensive drugs in severe symptomatic aortic stenosis (risk
    of severe hypotension, syncope).
  substances: []
  enabled: true
  phase: STOPP
- id: B21
  description: Digoxin as first line treatment for long-term (> 3 months) ventricular
    rate control in atrial fibrillation (increased mortality from long-term digoxin
    use; cardio-selective beta-blockers are generally preferable).
  substances: []
  enabled: true
  phase: STOPP
- id: C1
  description: Long-term aspirin at doses greater than 100mg per day (increased risk
    of bleeding, no evidence for increased efficacy).
  substances: []
  enabled: true
  phase: STOPP
- id: C2
  description: Antiplatelet agents, vitamin K antagonists, direct thrombin inhibitors
    or factor Xa inhibitors with concurrent significant risk of major bleeding, i.e.
    uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous
    bleeding (high risk of bleeding).
  substances: []
  enabled: true
  phase: STOPP
- id: C3
  description: Aspirin plus clopidogrel as long-term secondary stroke prevention i.e.,
    > 4 weeks, unless the patient has a coronary stent(s) inserted in the previous
    12 months or concurrent acute coronary syndrome or has a high grade symptomatic
    carotid arterial stenosis (no evidence of added long-term benefit over clopidogrel
    monotherapy).
  substances: []
  enabled: true
  phase: STOPP
- id: C4
  description: Antiplatelet agents in combination with vitamin K antagonist, direct
    thrombin inhibitor or factor Xa inhibitors in patients with chronic atrial fibrillation,
    unless there is concurrent coronary artery stent(s) inserted or angiographically
    proven high grade (> 50%) coronary artery stenosis (no added benefit from antiplatelet
    agents).
  substances: []
  enabled: true
  phase: STOPP
- id: C5
  description: Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor
    or factor Xa inhibitors in patients with stable coronary, cerebrovascular or peripheral
    arterial disease (no evidence of added benefit from dual therapy).
  substances: []
  enabled: true
  phase: STOPP
- id: C6
  description: Ticlopidine in any circumstances (clopidogrel and prasugrel have similar
    efficacy, stronger evidence and fewer side-effects).
  substances: []
  enabled: true
  phase: STOPP
- id: C7
  description: Antiplatelet agents as alternatives to vitamin K antagonists, direct
    thrombin inhibitors or factor Xa inhibitors for stroke prevention in patients
    with chronic atrial fibrillation (no evidence of efficacy).
  substances: []
  enabled: true
  phase: STOPP
- id: C8
  description: Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors
    for first deep venous thrombosis without continuing provoking risk factors (e.g.,
    thrombophilia) for longer than 6 months, (no proven added benefit).
  substances: []
  enabled: true
  phase: STOPP
- id: C9
  description: Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors
    for first pulmonary embolus without continuing provoking risk factors (e.g., thrombophilia)
    for longer than 12 months (no proven added benefit).
  substances: []
  enabled: true
  phase: STOPP
- id: C10
  description: Nonsteroidal anti-inflammatory drugs (NSAIDs) and vitamin K antagonist,
    direct thrombin inhibitor or factor Xa inhibitors in combination (risk of major
    gastrointestinal bleeding).
  substances:
  - NSAID
  enabled: true
  phase: STOPP
- id: C11
  description: Vitamin K antagonist as first-line anticoagulant for atrial fibrillation,
    unless there is concurrent metallic heart valve in-situ, moderate-to-severe mitral
    stenosis, or eGFR < 15 mls/min./1.73m2 (direct thrombin inhibitors or factor Xa
    inhibitors are equally efficacious and safer than vitamin K antagonists).
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: C12
  description: Selective serotonin reuptake inhibitors (SSRIs) in combination with
    Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitor with a
    previous history of major haemorrhage (increased risk of bleeding due to antiplatelet
    effects of SSRIs).
  substances:
  - SSRI
  enabled: true
  phase: STOPP
- id: C13
  description: Direct thrombin inhibitor (e.g., dabigatran) and diltiazem or verapamil
    (increased risk of bleeding).
  substances: []
  enabled: true
  phase: STOPP
- id: C14
  description: Apixaban, dabigatran, edoxaban, rivaroxaban and P-glycoprotein (P-gp)
    drug efflux pump inhibitors e.g., amiodarone, azithromycin, carvedilol, cyclosporin,
    dronedarone, itraconazole, ketoconazole (systemic), macrolides, quinine, ranolazine,
    tamoxifen, ticagrelor, verapamil (increased risk of bleeding).
  substances: []
  enabled: true
  phase: STOPP
- id: C15
  description: Systemic oestrogens or androgens with pervious history of venous thromboembolism
    (increased risk of recurrent venous thromboembolism).
  substances: []
  enabled: true
  phase: STOPP
- id: C16
  description: Aspirin for primary prevention in cardiovascular disease (no evidence
    of benefit).
  substances: []
  enabled: true
  phase: STOPP
- id: D1
  description: TriCyclic Antidepressants (TCAs) in patients with dementia, narrow
    angle glaucoma, cardiac conduction abnormalities, prostatism, chronic constipation,
    recent falls, prior history of urinary retention or orthostatic hypotension (risk
    of worsening these conditions).
  substances:
  - TCA
  enabled: true
  phase: STOPP
- id: D2
  description: Initiation of TriCyclic Antidepressants (TCAs) as first-line treatment
    for major depression (higher risk of adverse drug reactions with TCAs than with
    SSRIs or SNRIs).
  substances:
  - SNRI
  - SSRI
  - TCA
  enabled: true
  phase: STOPP
- id: D3
  description: Serotonin/noradrenaline reuptake inhibitors (SNRI’s e.g., venlafaxine,
    duloxetine) and severe hypertension i.e., systolic blood pressure > 180 mmHg +/-
    diastolic blood pressure > 105 mmHg (likely to make hypertension worse).
  substances:
  - SNRI
  enabled: true
  phase: STOPP
- id: D4
  description: Antipsychotics with moderate-marked antimuscarinic/anticholinergic
    effects (acepromazine, chlorpromazine, clozapine, flupenthixol, fluphenzine, levomepromazine,
    olanzapine, pipothiazine, promazine, thioridazine) with a history of lower urinary
    tract symptoms associated with benign prostatic hyperplasia or previous urinary
    retention (high risk of urinary retention).
  substances: []
  enabled: true
  phase: STOPP
- id: D5
  description: Antipsychotics prescribed for behavioural and psychological symptoms
    of dementia (BPSD) an unchanged dose for > 3 months without medication review
    (increased risk of extrapyramidal side-effects and chronic worsening of cognition,
    increased risk of major cardiovascular morbidity and mortality).
  substances:
  - BPSD
  enabled: true
  phase: STOPP
- id: D6
  description: Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent
    significant hyponatraemia i.e., serum Na+ < 130 mmol/l (risk of exacerbating or
    precipitating hyponatraemia).
  substances:
  - SSRI
  enabled: true
  phase: STOPP
- id: D7
  description: Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent
    significant bleeding (risk of exacerbation or recurrence of bleeding due to antiplatelet
    effects of SSRI’s).
  substances:
  - SSRI
  enabled: true
  phase: STOPP
- id: D8
  description: Benzodiazepines for ≥ 4 weeks (no indication for longer treatment;
    risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents;
    all benzodiazepines should be withdrawn gradually if taken for more than 4 weeks
    as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped
    abruptly).
  substances: []
  enabled: true
  phase: STOPP
- id: D9
  description: Benzodiazepines for agitated behaviour or psychotic symptoms of dementia
    (no evidence of efficacy).
  substances: []
  enabled: true
  phase: STOPP
- id: D10
  description: Benzodiazepines for insomnia for ≥ 2 weeks (high risk of dependency,
    increased risk of falls, fractures and road traffic accidents).
  substances: []
  enabled: true
  phase: STOPP
- id: D11
  description: Z-drugs (zolpidem, zopiclone, zaleplon) for insomnia for ≥ 2 weeks
    (increased risk of falls, fractures).
  substances: []
  enabled: true
  phase: STOPP
- id: D12
  description: Antipsychotics (i.e., other than clozapine or quetiapine) in those
    with parkinsonism or Dementia with Lewy Bodies (risk of severe extra-pyramidal
    symptoms).
  substances: []
  enabled: true
  phase: STOPP
- id: D13
  description: Anticholinergic/antimuscarinic drugs (biperiden, orphenadrine, procyclidine,
    trihexyphenidyl) to treat extra-pyramidal side-effects of antipsychotic medications
    (risk of anticholinergic toxicity).
  substances: []
  enabled: true
  phase: STOPP
- id: D14
  description: Drugs with potent anticholinergics/antimuscarinic effects** in patients
    with delirium or dementia (risk of exacerbation of cognitive impairment). ** Commonly
    prescribed drugs with potent anticholinergic/ antimuscarinic effects include tricyclic
    antidepressants (e.g., amitriptyline, doxepin, impramine, nortriptyline), antipsychotics
    (chlorpromazine, clozapine, thioridazine), first generation antihistamines (e.g.,
    diphenhydramine, chlorpheniramine), bladder anti-spasmodics (e.g., tolterodine,
    oxybutynin), hyoscine, procyclidine, benzatropine, tizanidine.
  substances: []
  enabled: true
  phase: STOPP
- id: D15
  description: Antipsychotics in patients with behavioural and psychological symptoms
    of dementia (BPSD) for longer than 12 weeks unless BPSD symptoms are severe and
    other non- pharmacological treatments have failed (increased risk of stroke, myocardial
    infarction).
  substances:
  - BPSD
  enabled: true
  phase: STOPP
- id: D16
  description: Antipsychotics as hypnotics, unless sleep disorder is due to psychosis
    or BPSD effects of dementia (not recommended in summary of product characteristics;
    increased risk of confusion, hypotension, extra-pyramidal side effects, falls).
  substances:
  - BPSD
  enabled: true
  phase: STOPP
- id: D17
  description: Acetylcholinesterase inhibitors with a known history of persistent
    bradycardia (< 60 beats/min.), heart block or recurrent unexplained syncope (risk
    of cardiac conduction failure, syncope and injury).
  substances: []
  enabled: true
  phase: STOPP
- id: D18
  description: Acetylcholinesterase inhibitors with concurrent treatment with drugs
    that induce persistent bradycardia (< 60 beats/min.) such as beta-blockers, digoxin,
    diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury).
  substances: []
  enabled: true
  phase: STOPP
- id: D19
  description: Memantine with known current or previous seizure disorder (increased
    risk of seizures).
  substances: []
  enabled: true
  phase: STOPP
- id: D20
  description: Nootropics in dementia including Gingko Biloba, piracetam, pramiracetam,
    phenylpiracetam, aniracetam, phosphatidylserine, modafinil, L-theanine, omega-3
    fatty acids, panax ginseng, rhodiola, creatine (no evidence of efficacy).
  substances: []
  enabled: true
  phase: STOPP
- id: D21
  description: Phenothiazines as first-line treatment for psychosis or non-cognitive
    symptoms of dementia, since safer and more efficacious alternatives exist (phenothiazines
    are sedative, have significant anti-muscarinic toxicity in older people, except
    for prochlorperazine for nausea/vomiting/vertigo, chlorpromazine for relief of
    persistent hiccoughs and levomepromazine as an anti-emetic in palliative care).
  substances: []
  enabled: true
  phase: STOPP
- id: D22
  description: Levodopa or dopamine agonists for benign essential tremor (no evidence
    of efficacy)
  substances: []
  enabled: true
  phase: STOPP
- id: D23
  description: Levodopa or dopamine agonists for treatment of extrapyramidal side-effects
    of antipsychotics or other forms of drug-induced Parkinsonism (inappropriate prescribing
    cascade to be avoided).
  substances: []
  enabled: true
  phase: STOPP
- id: D24
  description: First-generation antihistamines as first-line treatment for allergy
    or pruritus (safer antihistamines with fewer side-effects now widely available).
  substances: []
  enabled: true
  phase: STOPP
- id: D25
  description: First-generation antihistamines for insomnia (high risk of side-effects,
    Z-drugs safer and more appropriate for short-term use).
  substances: []
  enabled: true
  phase: STOPP
- id: E1
  description: Digoxin at a long-term (i.e. more than 90 days) maintenance dose ≥
    125μg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin toxicity if plasma levels
    not measured).
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E2
  description: Direct thrombin inhibitors (e.g., dabigatran) if eGFR < 30 ml/min/1.73m2
    (risk of bleeding)
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E3
  description: Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban) if eGFR
    < 15 ml/min/1.73m2 (risk of bleeding)
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E4
  description: NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal
    function).
  substances:
  - GFR
  - NSAID
  enabled: true
  phase: STOPP
- id: E5
  description: Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity)
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E6
  description: Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis).
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E7
  description: Mineralocorticoid receptor antagonists (e.g. spironolactone, eplerenone)
    if eGFR < 30 ml/min/1.73m2 (risk of dangerous hyperkalaemia).
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E8
  description: Nitrofurantoin if eGFR < 45 ml/min/1.73m2 (increased risk of nitrofurantoin
    toxicity).
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E9
  description: Bisphosphonates if eGFR<30 ml/min/1.73m2 (increased risk of acute renal
    failure).
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: E10
  description: Methotrexate if eGFR <30 ml/min/1.73m2 (increased risk of methotrexate
    toxicity).
  substances:
  - GFR
  enabled: true
  phase: STOPP
- id: F1
  description: Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating
    Parkinsonian symptoms).
  substances: []
  enabled: true
  phase: STOPP
- id: F2
  description: Proton pump inhibitor (PPI) for uncomplicated peptic ulcer disease
    at full therapeutic dosage for > 8 weeks (dose reduction or earlier discontinuation
    or H2 antagonist maintenance therapy usually indicated).
  substances:
  - PPI
  enabled: true
  phase: STOPP
- id: F3
  description: Drugs likely to cause constipation (e.g. systemic antimuscarinics,
    oral iron, opioids, verapamil, aluminium antacids) with chronic constipation where
    non-constipating alternatives are available (risk of exacerbation of constipation).
  substances: []
  enabled: true
  phase: STOPP
- id: F4
  description: Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate>
    600 mg/day, ferrous sulphate > 600 mg/day, ferrous gluconate> 1800 mg/day; no
    evidence of enhanced iron absorption above these doses).
  substances: []
  enabled: true
  phase: STOPP
- id: F5
  description: Corticosteroids with a history of peptic ulcer disease or erosive oesophagitis
    (risk of relapse unless proton pump inhibitor is co-prescribed).
  substances: []
  enabled: true
  phase: STOPP
- id: F6
  description: Antiplatelet or anticoagulant drugs with a history of Gastric Antral
    Vascular Ectasia (GAVE, “watermelon stomach”) (risk of major gastrointestinal
    bleeding).
  substances:
  - GAVE
  enabled: true
  phase: STOPP
- id: F7
  description: Antipsychotics with dysphagia (increased risk of aspiration pneumonia).
  substances: []
  enabled: true
  phase: STOPP
- id: F8
  description: Megestrol acetate to increase appetite (increased risk of thrombosis
    and death with unproven efficacy)
  substances: []
  enabled: true
  phase: STOPP
- id: G1
  description: Theophylline as monotherapy for COPD (safer, more effective alternative;
    risk of adverse effects due to narrow therapeutic index).
  substances:
  - COPD
  enabled: true
  phase: STOPP
- id: G2
  description: Systemic corticosteroids instead of inhaled corticosteroids for maintenance
    therapy in moderate-severe COPD (unnecessary exposure to long-term side-effects
    of systemic corticosteroids and effective inhaled therapies are available).
  substances:
  - COPD
  enabled: true
  phase: STOPP
- id: G3
  description: Long-acting muscarinic antagonists (e.g., tiotropium, aclidinium, umeclidinium,
    glycopyrronium) with a history of narrow angle glaucoma (may exacerbate glaucoma)
    or bladder outflow obstruction (may cause urinary retention).
  substances: []
  enabled: true
  phase: STOPP
- id: G4
  description: Benzodiazepines with acute or chronic respiratory failure i.e. pO2
    < 8.0 kPa ± pCO2 > 6.5 kPa (risk of exacerbation of respiratory failure).
  substances: []
  enabled: true
  phase: STOPP
- id: H1
  description: Non-steroidal anti-inflammatory drugs (NSAIDs) other than COX-2 selective
    agents with history of peptic ulcer disease or gastrointestinal bleeding, unless
    with concurrent PPI or H2 antagonist (risk of peptic ulcer relapse).
  substances:
  - COX-
  - NSAID
  - PPI
  enabled: true
  phase: STOPP
- id: H2
  description: NSAID’s with severe hypertension i.e., systolic blood pressure consistently
    above 170 mmHg and/or diastolic blood pressure consistently above 100 mmHg (risk
    of exacerbation of hypertension).
  substances:
  - NSAID
  enabled: true
  phase: STOPP
- id: H3
  description: Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis
    pain where paracetamol has not been tried (simple analgesics preferable and usually
    as effective for pain relief and safer).
  substances:
  - NSAID
  enabled: true
  phase: STOPP
- id: H4
  description: Long-term corticosteroids (>3 months) as monotherapy for rheumatoid
    arthritis (risk of systemic corticosteroid side-effects).
  substances: []
  enabled: true
  phase: STOPP
- id: H5
  description: Corticosteroids (other than periodic intra-articular injections for
    mono-articular pain) for osteoarthritis (risk of systemic corticosteroid side-effects).
  substances: []
  enabled: true
  phase: STOPP
- id: H6
  description: Long-term NSAID or colchicine (>3 months) for chronic treatment of
    gout where there is no contraindication to a xanthine-oxidase inhibitor (e.g.,
    allopurinol, febuxostat) (xanthine- oxidase inhibitors are first choice prophylactic
    drugs in gout).
  substances:
  - NSAID
  enabled: true
  phase: STOPP
- id: H7
  description: NSAID with concurrent corticosteroids for treatment of arthritis/rheumatism
    of any kind (increased risk of peptic ulcer disease).
  substances:
  - NSAID
  enabled: true
  phase: STOPP
- id: H8
  description: Oral bisphosphonates in patients with a current or recent history of
    upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis,
    or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation
    of oesophagitis, oesophageal ulcer, oesophageal stricture).
  substances: []
  enabled: true
  phase: STOPP
- id: H9
  description: Long-term opioids for osteoarthritis (lack of evidence of efficacy,
    increased risk of serious side-effects).
  substances: []
  enabled: true
  phase: STOPP
- id: I1
  description: Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium)
    with dementia or chronic cognitive impairment (risk of increased confusion, agitation).
  substances: []
  enabled: true
  phase: STOPP
- id: I2
  description: Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium)
    with narrow-angle glaucoma (risk of acute exacerbation of glaucoma).
  substances: []
  enabled: true
  phase: STOPP
- id: I3
  description: Systemic antimuscarinic (e.g., oxybutynin, tolterodine, trospium) drugs
    for lower urinary tract symptoms with benign prostatic hyperplasia (BPH) and high
    post-void residual volume i.e. > 200 ml (uncertain efficacy and increased risk
    of urinary retention in older men).
  substances:
  - BPH
  enabled: true
  phase: STOPP
- id: I4
  description: Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium)
    with constipation (risk of exacerbation of constipation).
  substances: []
  enabled: true
  phase: STOPP
- id: I5
  description: Alpha-1 receptor antagonists other than silodosin (e.g., alfuzosin,
    doxazosin, indoramin, tamsulosin, terazosin) with symptomatic orthostatic hypotension
    or history of syncope (risk of precipitating recurrent syncope).
  substances: []
  enabled: true
  phase: STOPP
- id: I6
  description: Mirabegron in labile or severe hypertension (risk of exacerbation of
    hypertension).
  substances: []
  enabled: true
  phase: STOPP
- id: I7
  description: Duloxetine with urinary urgency or urge incontinence (duloxetine is
    indicated in stress incontinence but not in urinary urgency or urge incontinence).
  substances: []
  enabled: true
  phase: STOPP
- id: I8
  description: Antibiotic use in asymptomatic bacteriuria (no indication for treatment).
    Section J. Endocrine System
  substances: []
  enabled: true
  phase: STOPP
- id: I1
  description: Sulphonylureas with a long half-life (e.g., glibenclamide, chlorpropamide,
    glimepiride) with type 2 diabetes mellitus (risk of prolonged hypoglycaemia).
  substances: []
  enabled: true
  phase: STOPP
- id: I2
  description: Thiazolidenediones (e.g., rosiglitazone, pioglitazone) with heart failure
    (risk of exacerbation of heart failure).
  substances: []
  enabled: true
  phase: STOPP
- id: I3
  description: Non-selective beta-blockers in diabetes mellitus with frequent hypoglycaemic
    episodes (risk of suppressing hypoglycaemic symptoms).
  substances: []
  enabled: true
  phase: STOPP
- id: I4
  description: Sodium glucose co-transporter (SGLT2) inhibitors (e.g., canagliflozin,
    dapagliflozin, empagliflozin, ertugliflozin) with symptomatic hypotension (risk
    of exacerbation of hypotension).
  substances:
  - SGLT
  enabled: true
  phase: STOPP
- id: I5
  description: Systemic oestrogens with a history of breast cancer (increased risk
    of recurrence).
  substances: []
  enabled: true
  phase: STOPP
- id: I6
  description: Systemic oestrogens with a history of venous thromboembolism (increased
    risk of recurrence).
  substances: []
  enabled: true
  phase: STOPP
- id: I7
  description: Menopausal hormone therapy (oestrogen plus progestin) with a history
    of stenotic coronary, cerebral or peripheral arterial disease (increased risk
    of acute arterial thrombosis).
  substances: []
  enabled: true
  phase: STOPP
- id: I8
  description: Systemic oestrogens without progestogens in patients with intact uterus
    (risk of endometrial cancer).
  substances: []
  enabled: true
  phase: STOPP
- id: I9
  description: Levothyroxine in subclinical hypothyroidism i.e., normal free T4, elevated
    TSH but < 10 mU/L (no evidence of benefit, risk of iatrogenic thyrotoxicosis).
  substances:
  - TSH
  enabled: true
  phase: STOPP
- id: I10
  description: Vasopressin analogues (e.g., desmopressin, vasopressin) for urinary
    incontinence or urinary frequency (risk of symptomatic hyponatraemia).
  substances: []
  enabled: true
  phase: STOPP
- id: K1
  description: Benzodiazepines in patients with recurrent falls (may cause reduced
    sensorium, impair balance).
  substances: []
  enabled: true
  phase: STOPP
- id: K2
  description: Antipsychotic drugs in patients with recurrent falls (may cause Parkinsonism).
  substances: []
  enabled: true
  phase: STOPP
- id: K3
  description: Vasodilator drugs in patients with recurrent falls with persistent
    postural hypotension i.e., systolic BP drop ≥ 20 mmHg and/or diastolic BP drop
    ≥ 10 mmHg (risk of syncope, falls).
  substances: []
  enabled: true
  phase: STOPP
- id: K4
  description: Hypnotic Z-drugs i.e., zopiclone, zolpidem, zaleplon in patients with
    recurrent falls (may cause protracted daytime sedation, ataxia).
  substances: []
  enabled: true
  phase: STOPP
- id: K5
  description: Anti-epileptic drugs in patients with recurrent falls (may impair sensorium,
    may adversely affect cerebellar function).
  substances: []
  enabled: true
  phase: STOPP
- id: K6
  description: First generation antihistamines in patients with recurrent falls (may
    impair sensorium).
  substances: []
  enabled: true
  phase: STOPP
- id: K7
  description: Opioids in patients with recurrent falls (may impair sensorium).
  substances: []
  enabled: true
  phase: STOPP
- id: K8
  description: Antidepressants in patients with recurrent falls (may impair sensorium).
  substances: []
  enabled: true
  phase: STOPP
- id: K9
  description: Alpha blockers as antihypertensives in patients with recurrent falls
    (may cause orthostatic hypotension).
  substances: []
  enabled: true
  phase: STOPP
- id: K10
  description: Alpha blockers for prostatic bladder outflow symptoms, other than silodosin
    in patients with recurrent falls (may cause orthostatic hypotension).
  substances: []
  enabled: true
  phase: STOPP
- id: K11
  description: Centrally acting antihypertensives (may impair sensorium and may cause
    orthostatic hypotension).
  substances: []
  enabled: true
  phase: STOPP
- id: K12
  description: Antimuscarinics for treatment of overactive bladder or urge incontinence
    (may impair sensorium).
  substances: []
  enabled: true
  phase: STOPP
- id: L1
  description: Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl,
    buprenorphine, diamorphine, methadone, tramadol, pethidine, pentazocine) as first
    line therapy for mild pain (WHO analgesic ladder not observed; paracetamol or
    NSAID not prescribed as first-line therapy).
  substances:
  - NSAID
  - WHO
  enabled: true
  phase: STOPP
- id: L2
  description: Use of daily regular (as distinct from PRN) opioids without concomitant
    laxative (risk of severe constipation).
  substances:
  - PRN
  enabled: true
  phase: STOPP
- id: L3
  description: Long-acting opioids without short-acting opioids for break-through
    moderate or severe pain (risk of persistence of severe pain).
  substances: []
  enabled: true
  phase: STOPP
- id: L4
  description: Topical lidocaine (lignocaine) patch for treatment of chronic osteoarthritis
    pain (lack of evidence of efficacy).
  substances: []
  enabled: true
  phase: STOPP
- id: L5
  description: Gabapentinoids (e.g., gabapentin, pregabalin) for non-neuropathic pain
    (lack of evidence of efficacy).
  substances: []
  enabled: true
  phase: STOPP
- id: L6
  description: Paracetamol at doses ≥ 3 g/24 hours in patients with poor nutritional
    status i.e., BMI < 18 or chronic liver disease (risk of hepatotoxicity).
  substances:
  - BMI
  enabled: true
  phase: STOPP
- id: M1
  description: Concomitant use of two or more drugs with antimuscarinic/anticholinergic
    properties (e.g., bladder antispasmodics, intestinal antispasmodics, tricyclic
    antidepressants, first generation antihistamines, antipsychotics) (risk of increased
    antimuscarinic/anticholinergic toxicity).
  substances: []
  enabled: true
  phase: STOPP
- id: A1
  description: Where a drug is clearly indicated and considered appropriate in the
    particular clinical context and there is no clear contraindication, that drug
    should be initiated as per formulary guidelines for dose and duration.
  substances: []
  enabled: true
  phase: START
- id: B1
  description: Antihypertensive therapy where systolic blood pressure > 140 mmHg and
    /or diastolic blood pressure > 90 mmHg, unless established moderate or severe
    physical frailty in whom the threshold for therapy is 150 mmHg systolic pressure
    and/or 90 mmHg diastolic pressure.
  substances: []
  enabled: true
  phase: START
- id: B2
  description: Statin therapy with a documented history of coronary, cerebral or peripheral
    vascular disease, unless the patient’s status is end-of-life or established moderate
    or severe frailty.
  substances: []
  enabled: true
  phase: START
- id: B3
  description: Angiotensin Converting Enzyme (ACE) inhibitor with coronary artery
    disease.
  substances:
  - ACE
  enabled: true
  phase: START
- id: B4
  description: Beta-blocker with symptomatic coronary artery disease.
  substances: []
  enabled: true
  phase: START
- id: B5
  description: Angiotensin Converting Enzyme (ACE) inhibitor for heart failure with
    reduced ejection fraction.
  substances:
  - ACE
  enabled: true
  phase: START
- id: B6
  description: Cardio-selective beta-blocker (bisoprolol, nebivolol, metoprolol or
    carvedilol) for stable heart failure with reduced ejection fraction.
  substances: []
  enabled: true
  phase: START
- id: B7
  description: Mineralocorticoid receptor antagonist (spironolactone, eplerenone)
    in heart failure without severe renal function impairment i.e., eGFR > 30 ml/min/m2.
  substances:
  - GFR
  enabled: true
  phase: START
- id: B8
  description: SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
    in symptomatic heart failure with or without reduced ejection fraction regardless
    of diabetes being present or not.
  substances:
  - SGLT-
  enabled: true
  phase: START
- id: B9
  description: Sacubitril/valsartan in heart failure with reduced ejection fraction
    causing persistent heart failure symptoms despite optimal dose of ACE inhibitor
    or Angiotensin Receptor Blocker (Sacubitril/valsartan to replace ACE inhibitor
    or Angiotensin Receptor Blocker).
  substances:
  - ACE
  enabled: true
  phase: START
- id: B10
  description: Beta-blocker for chronic atrial fibrillation with uncontrolled heart
    rate.
  substances: []
  enabled: true
  phase: START
- id: B11
  description: Intravenous iron for symptomatic heart failure with reduced ejection
    fraction and iron deficiency.
  substances: []
  enabled: true
  phase: START
- id: C1
  description: Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors
    in the presence of chronic or paroxysmal atrial fibrillation.
  substances: []
  enabled: true
  phase: START
- id: C2
  description: Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor)
    with a documented history of coronary, cerebral or peripheral vascular disease.
  substances: []
  enabled: true
  phase: START
- id: D1
  description: L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with
    functional impairment and resultant disability.
  substances:
  - L-DOPA
  enabled: true
  phase: START
- id: D2
  description: Non-TCA antidepressant for major depression.
  substances:
  - TCA
  enabled: true
  phase: START
- id: D3
  description: Acetylcholinesterase inhibitor (donepezil, rivastigmine, galantamine)
    for mild-moderate Alzheimer’s dementia.
  substances: []
  enabled: true
  phase: START
- id: D4
  description: Rivastigmine for Dementia with Lewy Bodies or Parkinson’s disease dementia.
  substances: []
  enabled: true
  phase: START
- id: D5
  description: Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI
    contraindicated) for persistent severe anxiety that affects independent functioning
    and quality of life.
  substances:
  - SNRI
  - SSRI
  enabled: true
  phase: START
- id: D6
  description: Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless
    Legs Syndrome, once iron deficiency and severe chronic kidney disease (i.e., eGFR
    < 30 ml/min/m2) have been excluded.
  substances:
  - GFR
  enabled: true
  phase: START
- id: D7
  description: Propranolol for essential tremor with functional impairment and resultant
    disability.
  substances: []
  enabled: true
  phase: START
- id: E1
  description: One-alpha hydroxycholecalciferol or calcitriol supplementation in severe
    chronic kidney (i.e., eGFR < 30 ml/min/m2) disease with hypocalcaemia (corrected
    serum calcium < 2.10 mmol/l) and associated secondary hyperparathyroidism.
  substances:
  - GFR
  enabled: true
  phase: START
- id: E2
  description: Phosphate binder in severe chronic kidney disease (i.e., eGFR < 30
    ml/min/m2) if serum phosphate concentration persistently >1.76 mmol/l (5.5 mg/dl)
    despite adherence to renal diet.
  substances:
  - GFR
  enabled: true
  phase: START
- id: E3
  description: Erythopoietin analogue in severe chronic kidney disease (i.e., eGFR
    < 30 ml/min/m2) with symptomatic anaemia not attributable to haematinic or iron
    deficiency to achieve a haemoglobin concentration of 10.0 to 12.0 g/dl.
  substances:
  - GFR
  enabled: true
  phase: START
- id: E4
  description: Angiotensin receptor blocker (ARB) or Angiotensin Converting Enzyme
    Inhibitor (ACE-I) in chronic kidney disease with proteinuria i.e., urine albumin
    excretion >300 mg/24 hours.
  substances:
  - ACE-I
  - ARB
  enabled: true
  phase: START
- id: F1
  description: Proton Pump Inhibitor with severe gastro-oesophageal reflux disease
    or peptic oesophageal stricture requiring dilatation.
  substances: []
  enabled: true
  phase: START
- id: F2
  description: Proton pump inhibitor with initiation of low-dose aspirin and previous
    history of peptic ulcer or reflux oesophagitis.
  substances: []
  enabled: true
  phase: START
- id: F3
  description: Proton pump inhibitor with short-term (< 2 weeks) or longer-term (>
    2 weeks) NSAID.
  substances:
  - NSAID
  enabled: true
  phase: START
- id: F4
  description: Fibre supplements (e.g., bran, ispaghula, methylcellulose, sterculia)
    for diverticulosis with a history of constipation.
  substances: []
  enabled: true
  phase: START
- id: F5
  description: Osmotic laxative (e.g., lactulose, macrogol, sorbitol) for chronic
    persistent idiopathic or secondary benign constipation.
  substances: []
  enabled: true
  phase: START
- id: F6
  description: Probiotics used with antibiotics in patients who are not immunocompromised
    or severely debilitated for the prevention of Clostridioides difficile-associated
    diarrhoea.
  substances: []
  enabled: true
  phase: START
- id: F7
  description: Helicobacter pylori eradication therapy in HP-associated active peptic
    ulcer disease.
  substances:
  - HP-
  enabled: true
  phase: START
- id: G1
  description: Long-acting muscarinic antagonist (LAMA e.g., tiotropium, aclidinium,
    umeclidinium, glycopyrronium) or long-acting beta 2 agonist (LABA e.g., bambuterol,
    formoterol, indacaterol, olodaterol, salmeterol) for symptomatic COPD of GOLD
    1 or 2 severity and chronic asthma.
  substances:
  - COPD
  - GOLD
  - LABA
  - LAMA
  enabled: true
  phase: START
- id: G2
  description: Regular i.e. daily inhaled corticosteroid (e.g., beclomethasone, budesonide,
    ciclesonide, fluticasone, mometasone) for moderate-severe asthma or COPD of GOLD
    3 or 4 severity, where FEV1 <50% of predicted value and repeated exacerbations
    requiring treatment with oral corticosteroids.
  substances:
  - COPD
  - FEV
  - GOLD
  enabled: true
  phase: START
- id: G3
  description: Home continuous oxygen with documented chronic hypoxaemia (i.e., pO2
    < 8.0 kPa or 60 mmHg or SaO2 < 89%).
  substances: []
  enabled: true
  phase: START
- id: H1
  description: Disease-modifying anti-rheumatic drug (DMARD) with chronic, active
    and disabling rheumatoid arthritis.
  substances:
  - DMARD
  enabled: true
  phase: START
- id: H2
  description: Bisphosphonates and vitamin D and calcium in patients taking long-term
    systemic corticosteroid therapy for prevention of steroid-induced osteoporosis.
  substances: []
  enabled: true
  phase: START
- id: H3
  description: Vitamin D in patients with known osteoporosis and/or previous fragility
    fracture(s) and/or Bone Mineral Density T-scores below -2.5 in one or multiple
    sites.
  substances: []
  enabled: true
  phase: START
- id: H4
  description: Bone anti-resorptive or anabolic therapy (e.g., bisphosphonate, teriparatide,
    denosumab) in patients with documented osteoporosis (Bone Mineral Density T-scores
    below -2.5 in one or multiple sites) and/or previous history of fragility fracture(s)
    – where no pharmacological or clinical status contraindication exists such as
    poor one-year life expectancy.
  substances: []
  enabled: true
  phase: START
- id: H5
  description: Vitamin D supplement in older people with confirmed 25-hydroxycolecalciferol
    deficiency (< 20 micrograms/L, < 50 nmol/L) who are housebound or experiencing
    falls or with osteopenia (Bone Mineral Density T-score is less than -1.0 but above
    -2.5 in one or multiple sites).
  substances: []
  enabled: true
  phase: START
- id: H6
  description: Anti-resorptive treatment after discontinuation of at least two doses
    of denosumab (rebound increased bone turnover markers, BMD loss, and increased
    risk of vertebral fracture following denosumab discontinuation).
  substances:
  - BMD
  enabled: true
  phase: START
- id: H7
  description: Anti-resorptive treatment after discontinuation of teriparatide/abaloparatide
    treatment for osteoporosis.
  substances: []
  enabled: true
  phase: START
- id: H8
  description: Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) with a history
    of recurrent episodes of gout.
  substances: []
  enabled: true
  phase: START
- id: H9
  description: Folic acid supplement in patients taking methotrexate.
  substances: []
  enabled: true
  phase: START
- id: I1
  description: Selective alpha-1 receptor blocker (e.g., tamsulosin, silodosin) for
    lower urinary tract symptoms related to benign prostatic hyperplasia where prostatectomy
    is not considered necessary or appropriate or safe.
  substances: []
  enabled: true
  phase: START
- id: I2
  description: 5-alpha reductase inhibitor (e.g., finasteride, dutasteride) for lower
    urinary tract symptoms related to benign prostatic hyperplasia where prostatectomy
    is not considered necessary or appropriate or safe.
  substances: []
  enabled: true
  phase: START
- id: I3
  description: Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic
    atrophic vaginitis.
  substances: []
  enabled: true
  phase: START
- id: I4
  description: Topical vaginal oestrogen or vaginal oestrogen pessary in women for
    recurrent urinary tract infections.
  substances: []
  enabled: true
  phase: START
- id: I5
  description: Phosphodiesterase type-5 inhibitors (e.g., avanafil, sildenafil, tadalafil,
    vardenafil) for persistent erectile dysfunction that causes distress.
  substances: []
  enabled: true
  phase: START
- id: J1
  description: ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE
    inhibitor) in diabetes with evidence of renal disease i.e., dipstick proteinuria
    or microalbuminuria (>30 mg/24 hours) unless evidence of severe CKD (eGFR < 30
    ml/min/m2).
  substances:
  - ACE
  - CKD
  - GFR
  enabled: true
  phase: START
- id: K1
  description: High-potency opioids in moderate-severe non-arthritis pain, where paracetamol,
    NSAIDs or low-potency opioids are not appropriate to the pain severity or have
    been ineffective.
  substances:
  - NSAID
  enabled: true
  phase: START
- id: K2
  description: Laxatives in patients receiving opioids regularly i.e., other than
    PRN use.
  substances:
  - PRN
  enabled: true
  phase: START
- id: K3
  description: Topical 5% lidocaine (lignocaine) patch for localized neuropathic pain,
    e.g. post-herpetic neuralgia.
  substances: []
  enabled: true
  phase: START
- id: L1
  description: Seasonal influenza vaccine annually.
  substances: []
  enabled: true
  phase: START
- id: L2
  description: Pneumococcal vaccine at least once according to national guidelines.
  substances: []
  enabled: true
  phase: START
- id: L3
  description: Varicella-zoster vaccine according to national guidelines.
  substances: []
  enabled: true
  phase: START
- id: L4
  description: SARS-CoV2 vaccine according to national guidelines.
  substances:
  - SARS-C
  enabled: true
  phase: START
